None listed
Conditions
Brief summary
The aim of the current study is to conduct a non-randomised three-arm parallel controlled clinical trial comparing the cognitive, emotional, and functional outcomes of acute ischaemic stroke patients treated with ECR and t-PA, as well as those who receive no treatment (neither ECR nor t-PA) in the acute phase.
Interventions
Arm 1 Endovascular Clot Retrieval (ECR) ECR will be administered to eligible patients who have a stroke due to large vessel occlusion within 24 hours of stroke onset, per standard care, in a public hospital setting. Arm 2 Intravenous Tissue Plasminogen Activator (t-PA) t-PA will be administered to eligible patients who have a stroke at the standard dose of 0.9mg per kilogram within four and half hours of stroke onset, per standard care, in a public hospital setting. As this is a non-randomised trial, participants are assigned to arm 1 or arm 2 based on the treatment they receive from their medical team. For this study, participants are being assessed 3-months post-stroke. Retrospective data being collected relates to information about stroke severity and stroke location.
Sponsors
Eligibility
Inclusion criteria
Patients who have an ischaemic stroke and receive ECR, t-PA, or no treatment (standard care) in the acute phase (at the time of treatment on admission to stroke ward).
Exclusion criteria
Experienced cognitive impairment prior to having a stroke (indicated by a score of two or more on the AD8 Dementia Screening Interview). History of previous stroke or other neurological illness that is known to cause ongoing cognitive sequelae, History of brain injury or psychiatric illness. Did not speak fluent English before their stroke. Do not have the capacity to provide consent.